Neuro Startup Makes Debut With $20.9M From Novo, Johnson & Johnson Post author:Sam Post published:February 8, 2018 Post category:BioPharma Syndesi will work to modulate the synaptic vesicle protein SV2A. Source: BioSpace You Might Also Like Onxeo Reports First-Half 2017 Results And Business Update July 30, 2017 Targovax: Invitation To First Quarter 2017 Results Presentation Tuesday 25 April April 18, 2017 Hedge Fund Takes Another Shot at Biotech, This Time at Prothena November 7, 2017
